Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports
Go Back
View Our Subscription Options

Search

Descriptive Alt Text

Filters

Showing results 1,009–1,016 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
BioNTech SE Pumitamig - (China trial) 1L TNBC Phase 3 Ongoing Intravenous Oncology
BioNTech SE Trastuzumab pamirtecan (T-Pam) - (DYNASTY Breast-02) 2L+ HR+ BC Phase 3 Ongoing Intravenous Oncology
BioNTech SE Autogene cevumeran - (BNT122-01) Adj. CRC Phase 3 Ongoing Intravenous Oncology
BioNTech SE BNT327/PM8002 plus chemotherapy First-line small cell lung cancer (SCLC) Phase 2 Ongoing Intravenous Oncology
BioNTech SE BNT327-06 First line NSCLC Phase 2/3 Enrollment Initiation Intravenous Oncology
BioNTech SE Pumitamig - (China trial) 1L MSS-CRC Phase 2 Ongoing Intravenous Oncology
BioNTech SE Pumitamig - (ROSETTA Lung-01) 1L ES-SCLC Phase 2 Ongoing Intravenous Oncology
BioNTech SE Trastuzumab pamirtecan (T-Pam) 2L+ HER2-expressing endometrial cancer Phase 2 Ongoing Intravenous Oncology
1…125126127128129…553
Your trusted source for drug reimbursement data and buy-and-bill insights.
Platform
Resources
Tools
Search Drugs
Newsletter
Reimbursement updates, drug pricing news.
© 2026 BuyandBill.com, All Rights Reserved.
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, America's Health Insurance Plans, and Blue Cross and Blue Shield Association). CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.